An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer

scientific article published on November 2007

An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1158/1078-0432.CCR-07-0648
P698PubMed publication ID17975155

P50authorRobert L VessellaQ106509691
Ilsa ColemanQ114402120
P2093author name stringStephen R Plymate
Peter Nelson
Dale L Ludwig
Kathy Haugk
R Bruce Montgomery
Jennifer D Wu
Lillie Woodke
P433issue21
P407language of work or nameEnglishQ1860
P921main subjectprostate cancerQ181257
preproinsulinQ7240673
P304page(s)6429-6439
P577publication date2007-11-01
P1433published inClinical Cancer ResearchQ332253
P1476titleAn antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer
P478volume13

Reverse relations

cites work (P2860)
Q34336988Can we unlock the potential of IGF-1R inhibition in cancer therapy?
Q34712380Critical role of a survivin/TGF-β/mTORC1 axis in IGF-I-mediated growth of prostate epithelial cells
Q39711107Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells
Q37542952Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions
Q37876194Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer
Q37826274Future directions in castrate-resistant prostate cancer therapy.
Q37381766Implications of insulin-like growth factor-I for prostate cancer therapies
Q42837186Inhibition of the insulin-like growth factor-1 receptor enhances effects of simvastatin on prostate cancer cells in co-culture with bone
Q42248557Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone
Q29619495Insulin and insulin-like growth factor signalling in neoplasia
Q38641329Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies
Q38177688Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy
Q34551541Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels
Q35121509Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma is associated with increased autocrine of IGF1.
Q33642278Novel targeted therapeutics for metastatic castration-resistant prostate cancer.
Q35838821Oncogenic activation in prostate cancer progression and metastasis: Molecular insights and future challenges
Q37519616Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer
Q35603263Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation
Q35563844SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer
Q54650111Serial analysis of resected prostate cancer suggests up‐regulation of type 1 IGF receptor with disease progression
Q37310963Serially heterotransplanted human prostate tumours as an experimental model
Q37575815Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy
Q37859024Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer
Q39205279Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts
Q37344395Targeting of the protein interaction site between FAK and IGF-1R.
Q37304764The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer
Q42951499Transforming Growth Factor-{beta}-Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition

Search more.